Monday, November 2, 2015

CLEAN Study Highlighted at Dermatology Foundation Clinical Symposia

The highly esteemed Dermatology Foundation Clinical Symposia, held in February 2015, provided the latest clinically relevant research and information on various dermatologic disorders, including atopic dermatitis (AD). Lawrence D. Eichenfield, MD presented the keynote address on Improving Outcomes in Atopic Dermatitis that reviewed research on the efficacy of several AD treatments, including the use of bleach bath and a recently introduced sodium hypochlorite wash.

The CLEAN study (Herbert A et al 2014 AAD Poster #7728), found that the use of CLn® Body Wash (a sodium hypochlorite-formulated wash) led to significant decrease in AD in 40 pediatric study subjects. Specifically, the study found that when CLn was added to standard AD treatment disease severity scores decreased  34-44%  at 6 weeks when compared to baseline.

The results of using a sodium hypochlorite wash in staphylococcus aureus colonized pediatric patients with AD, with a percentage mean reduction from baseline at weeks 2 and 6, are depicted in the table below.

Assessment Tool
Eczema Area and Severity Index (EASI)
Body Surface Areas (BSA)
Investigator Global Assessment (IGA)
Pruritus Visual Analog Scale (VAS)
2 weeks
6 weeks

The Dermatology Foundation’s newsletter, Dermatology Focus, profiled Dr. Eichenfield’s review of AD, including the significant evidence-based progress in using current treatment modalities, the current efforts to fill important gaps affecting successful patient management, and the development of innovative, targeted therapies in the treatment of AD. Those factors that enable patients to achieve effective disease control—i.e., minimized rash, itch, allergies, comorbidities, and drug side effects and toxicities—were also highlighted.

Eichenfield discussed the reported value of sodium hypochlorite baths and washes, including the anti-inflammatory effect of a sodium hypochlorite solution when applied to the skin. The sodium hypochlorite solution was shown to block NF-kB-dependent genes in keratinocytes that lead to inflammation. Eichenfield also recognized the American Association of Dermatology (AAD) Guidelines of bathing in patients with AD as part of treatment and maintenance. Although baths are recommended, there is no standard for appropriate frequency or duration of baths. Neither the use of acidic spring water nor the addition of oils, emollients, and most other additives to bath water are recommended.

 “So much of what we encounter in AD is inadequate care of patients who can in reality be appropriately managed, and we want to minimize the percentage of patients who are inadequately controlled,” stated Dr. Eichenfield during the keynote address.

Atopic dermatitis is the most common form of eczema. Eczema is an inflammatory skin condition that causes skin to become dry, itchy, and red. CLn® Body Wash is one product in the family of CLn® Skin Care products that was created to elevate the life quality of people with impaired skin. All products in the line are dermatologist-developed and clinically tested. CLn® BodyWash is designed to cleanse skin prone to eczema, acne, and folliculitis without irritation and aids in the reduction of body odor. For more information on CLn® Skin Care, please visit:

Dermatology Foundation. DF clinical symposia: Proceedings 2015—Part I. Keynote address. Dermatology Focus. 2015; 34(1): 1-2. Retrieved November 2, 2015, from

Leung TH, Zhang LF, Wang J, Ning S, Knox SJ, Kim SK. Topical hypochlorite ameliorates NF-kB-mediated skin diseases in mice. J Clin Invest. 2013; 123(12): 5361-5370. doi: 10.1172/JCI70895.

PR Newswire (2015). New Study Shows CLn Body Wash Yields Significant Improvements as an Adjunctive Skin Cleanser in Moderate-to-Severe Eczema. Retrieved November 2, 2015, from

No comments:

Post a Comment